Dr.Omar Gonzalez Stem Cell Therapy Method
New Project 75

By: OmarGonzalezMD

View original post here:
Dr.Omar Gonzalez Stem Cell Therapy Method - Video

Recommendation and review posted by Bethany Smith

Angie the Chimp Receives Stemlogix Stem Cell Therapy
Angie the chimp received Stemlogix stem cell therapy to treat her torn ACL. Video is courtesy of WPTV - read the full article: Chimp with torn ACL receives stem cell treatment at http://www.wptv.com

By: StemLogixLLC

See the original post:
Angie the Chimp Receives Stemlogix Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Lady Receives Stemlogix Stem Cell Therapy
Lady received Stemlogix stem cell therapy to help with her severe arthritis in her hips! Watch Dr. Whalen, of LePar Animal Hospital in Evergreen Park, perform surgery and Stem Cell Therapy on Lady Bender, a 5 year old Mastiff with severe arthritis in the hips. Dr. Whalen has been treating her for severe arthritis since June of 2011. Lady #39;s condition was acute as she was not able to get up on her own. Lady was also overweight and gradually lost 20 lbs under Dr. Whalen #39;s care. The video also shows the process for Stem Cell Therapy, the collection and re-injection phase. Stem cells are harvested using the dog #39;s own fat tissue, then processed in-hospital and then re-injected into the joints that need it most. Concurrently to the Stem Cell treatment, Lady also undergoes cruciate ligament repair. Dr. Whalen is the first veterinarian in Illinois to perform stem cell therapy in-house. Video is courtesy of LePar Animal Hospital.

By: StemLogixLLC

Excerpt from:
Lady Receives Stemlogix Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Washington, Feb 1 (ANI): Scientists have decoded the genetic blueprint of the rock pigeon, revealing secrets about pigeons' Middle East origins, feral pigeons' kinship with escaped racing birds and how mutations give pigeons traits like feather head crests.

Michael Shapiro, a biologist at the University of Utah, conducted the research with Jun Wang of China's BGI-Shenzhen (formerly Beijing Genomics Institute) and other scientists from BGI, the University of Utah, Denmark's University of Copenhagen and the University of Texas M.D. Anderson Cancer Center in Houston.

"The research identified the genes contributing to variation in the avian head crest, using the domesticated pigeons that so fascinated and inspired Charles Darwin in developing his theory of natural selection," said George Gilchrist, program director in the National Science Foundation's (NSF) Division of Environmental Biology, which funded the research.

"This finding illustrates the power of comparative genomics," he noted.

Key results of this study include sequencing of the genome of the rock pigeon Columba livia, which is among the most common bird species.

Using software developed by paper co-author Mark Yandell, a geneticist at the University of Utah, the scientists revealed that a single mutation in a gene named EphB2 causes head and neck feathers to grow upward instead of downward, creating head crests.

"This same gene in humans has been implicated as a contributor to Alzheimer's disease, as well as prostate cancer and possibly other cancers," Shapiro said, noting that more than 80 of the 350 pigeon breeds have head crests, which play a role in attracting mates in many bird species.

The researchers found strong evidence that the EphB2 (Ephrin receptor B2) gene acts as an on-off switch to create a head crest when mutant, and no head crest when normal.

They also showed that the mutation and related changes in nearby DNA are shared by all crested pigeons, so the trait evolved just once and was spread to numerous pigeon breeds by breeders.

Full or partial genetic sequences were analyzed for 69 crested birds from 22 breeds, and 95 uncrested birds from 57 breeds. The biologists found a perfect association between the mutant gene and the presence of head crests.

See more here:
Mutant gene gives pigeons its head crests

Recommendation and review posted by Bethany Smith

Public release date: 1-Feb-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 31, 2012Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets. Two new methods for detecting and measuring the levels of antisense drugs in cells that could accelerate the development of improved antisense drugs are described in an article in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website.

In the article "Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells," Frederick Schnell, Stacy Crumley, Dan Mourich, and P.L. Iversen, from Sarepta Therapeutics and Oregon State University (Corvallis, OR), describe two fast and sensitive methods for detecting a promising type of antisense therapeutic called a phosphorodiamidate morpholine oligomer, or PMO. Using these novel methods they were able to detect PMO delivery to individual cells and quantify how much PMO resides in a particular tissue in the body, such as the lung. For example, the authors describe the measurement of intranasally delivered PMO in lung tissue and, more specifically, in different cell types in the lung. They were able to measure the clearance kinetics of the PMO and determine whether it stayed in the lung tissue.

"The development of novel, rapid PMO detection techniques such as these will advance the field of PMO research in a significant way, providing valid alternatives to the current time-consuming and labor-intensive methods," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Metabolic Syndrome and Related Disorders, Population Health Management, Diabetes Technology & Therapeutics, and Journal of Women's Health. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Go here to read the rest:
New methods for quantifying antisense drug delivery to target cells and tissues

Recommendation and review posted by Bethany Smith

An Article by Nature India.

There's a whiff of revolt at the New Delhi unit of the International Centre for Genetic Engineering and Biotechnology (ICGEB). In a step embarrassing the ICGEB governing board, a majority of senior scientists of the unit have expressed "no confidence" in their director Virandar Chauhan and have demanded his removal. The allegations against Chauhan range from mismanagement to lack of transparency and favouritism.

Chauhan did not deny that the scientists have complained against him. He said that the issues raised by these scientists had been resolved. "All issues raised about the running of the Centre by a group of anxious scientists have been addressed," he told Nature India.

In a letter signed by 24 out of 30 scientists in senior positions at the New Delhi campus the protestors have asked ICGEB director general Francisco Baralle to advise Chauhan to step down. Chauhan has been the director for the centre for last 15 years. The scientists have expressed displeasure at Chauhan's extension till the end of this year despite the recommendation of ICGEB's council of scientific advisors in October 2012 for "a formal review of Prof. Chauhan's performance as Component Director".

Baralle did not respond to a question on how he proposed to handle the revolt. However, he told the protesters in a letter dated December 18, 2012 that he needed to follow procedures. "The change of director or the new structure of the Delhi Component cannot be established without the agreement of the Indian authorities," he said.

Krishnaswamy Vijayaraghavan, who took charge of India government's Department of Biotechnology on January 28, 2013 told Nature India that any action on complaints against Chauhan will be decided "after a detailed investigation of the charges."

The complaints against Chauhan include lack of transparency in distribution of resources and hiring, victimisation of scientists and favouritism to certain research groups including his own on malaria. While a plant biology group was closed down, Chauhan created a new group on biofuels which he headed himself, it was alleged in the letter, a copy of which was made available to Nature India.

ICGEB has been functioning since 1994 as an autonomous, intergovernmental organization in the UN system with campuses in Trieste (Italy), New Delhi (India) and Cape Town (South Africa). The New Delhi component has till now been financed by Italy and India with 60% ($3 million) funds coming from Italy. However, this is likely to change from next year with Italy's decision to reduce its contribution

View post:
Indian biotechologists protest against management practices

Recommendation and review posted by Bethany Smith

Dr. Dan Kalish on Fox and Friends: Amino Acid Therapy
Dr. Daniel Kalish explaining the Kalish Method. Although highly controversial, the urine neurotransmitter test is said to measure the ratio and amount of dopamine and serotonin in one #39;s brain, at which point an amino acid therapy program can help to restore these values to a healthier range. This therapy is said to help cure everything from mild depression to brain toxicity and brain damage caused by heavy metals, traumatic events, and poor genetics. Editor #39;s note: I have been a patient of Dr. Kalish #39;s - and after 1.5 years of suffering from chronic headaches after contracting West Nile virus, this program was the only method to alleviate the headaches. There is a lot of controversy surrounding the effectiveness of urinary neurotransmitter testing, I #39;m not here to say that the testing is accurate or it isn #39;t the but the treatment based on this testing has made a huge positive impact on the quality of my life. If interested, you can read more at: theGoodBadger.com Visit Dr. Kalish #39;s website at http://www.kalishresearch.com

By: Zach Davis

Originally posted here:
Dr. Dan Kalish on Fox and Friends: Amino Acid Therapy - Video

Recommendation and review posted by Bethany Smith

Royal Queen Seedlings Update and Catnip Trimming Tutorial
Just a quick video showing how I maintain my catnip plants. Also, you get some views of the indoor medical cannabis garden, as well as my seedless kishu mandarin tangerine bonsai tree...Can you tell I was bored??? 🙂 Joery from Royal Queen Seeds was kind enough to send me some genetics to test out, here are the first 4 seed pops that I have to add to the garden. Shining Silver Haze 1, 2, and 3, as well as Royal Medic! So excited and appreciative. Thanks to Royal Queen Seeds and Joery, as well as thanks to all my subscribers! Love you all!!!

By: Theo M.

More:
Royal Queen Seedlings Update and Catnip Trimming Tutorial - Video

Recommendation and review posted by Bethany Smith

The Vnus Project - Vnus #39; voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com
The Vnus Project - Vnus #39; voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com Back-story of THE V-NUS PROJECT This is the story is of a young college student and science prodigy named Vnus Johnson, whose work with the TOP SECRET Project The "Addam009-AIC" (Artificial Intelligence Cyber-genetics) Project, takes her on a most interesting journey. This subdued and timid young lady was asked to join a top secret research team of five, charged with studying artificial intelligence/cyber genetics, funded by the a top robotics technology company, the Cyber Genetics Artificial Intelligence Corporation. Now in her senior year at a prominent University, Vnus Johnson, and the team that she leads are determined to create an artificially intelligent cyber genetic life form. However, as Vnus and her team get closer to a breakthrough, she becomes more distant, and more isolated, even from the team. Even her closest friends and family rarely see her. For the first time in Venus #39; life, this once shy and passive girl is starting to see her own beauty, and even more so... feel a strong yearning for companionship. Thus, she pulls away from the project and starts searching for that special someone. She tries the dating scene only to find one disappointment after another. Then late one night, as Vnus and her team gets closer to a breakthrough in creating a human-like cyber genetic life form, she gets an epiphany! While the Cyber Genetics Artificial Intelligence Corporation is "Paying ...

By: vwurld

See the original post here:
The Vnus Project - Vnus' voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com - Video

Recommendation and review posted by Bethany Smith

The John Report ( S07E22 )
Dale Ellis to miss rest of season ( SuperSonics ). Inventor of Aplets and Cotlets dies. Brian Bozworth movie to open in May ( Bo Jackson ). WSU seeks chair for department of Wheat Breeding and Genetics. Missing kegs from Rainier Brewery. West Seattle helicopter pad proposal. State representative Jolene Unsoeld opposes waiting period for handgun. Kingdome roof contractor finds cause of roof leaks ( Seattle Mariners ). Oregon men form "Male Pre-Menstrual Victims Association". First aired April 6, 1991 Copyright King 5 - Almost Live!

By: GeorgeBuford

Read the original here:
The John Report ( S07E22 ) - Video

Recommendation and review posted by Bethany Smith

Godfather Marijuana Review - LA Confidental x GrandaddyPurple - California Bud - Wisconsin Reviewers
Genetics: LA Confidential x Grand Daddy Purp Strain Name: Godfather (Sativa Dominant) Rating: 8/10 Looks: Light Green inside, Dark Green outside (outdoor), a lot of orange hairs, densely crystallized, hints of purple on end of bud. Smell: Fruity, with a hint of piney Taste: Piney, Fruity, Strong after taste Buzz Type: Longggggggg, Head high, Cheeked Out, Munchies, Makes Music/Movies better Buzz Length:30min-1hr Strong High, Chill after effect Overall: Decent Bud, Great Daytime Smoke, Generates Happiness, Would get again Thanks for watching our first video!! Subscribe to our channel for more marijuana videos!

By: WisconsinHeliumShow

Here is the original post:
Godfather Marijuana Review - LA Confidental x GrandaddyPurple - California Bud - Wisconsin Reviewers - Video

Recommendation and review posted by Bethany Smith

Hiding From Ghillie. The Hidden. Ep. 1.
Shenanigans on the Hatventures Hidden server. Forgive us for the video settings, but the creases #39;ll be worked out soon. The Hidden: "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and ...

By: ArroyoCast

Read more:
Hiding From Ghillie. The Hidden. Ep. 1. - Video

Recommendation and review posted by Bethany Smith

Strain Review : Chocolope (Own Grow)
Doing a review on my own hydro grown Chocolope. A really nice strain, a nice sativa with a awesome sweet taste almost like a japanese sweet tea with a small hint of chocolate on the exhale. A nice cerebral high, very injoyable. A big thanks to BigBudSmoker for the seeds, awesome genetics hands down. **www.youtube.com AKA BigBudSmoker Viewers 18+ only plz. Thanks for wacthing, please subscribe thumbs up Overgrow the World Free the Weed

By: cyberreload

The rest is here:
Strain Review : Chocolope (Own Grow) - Video

Recommendation and review posted by Bethany Smith

The Perfect 46 Super Bowl Commercial A
Super Bowl Commercial for The Perfect 46, a genetics company.

By: Jesse Darden

Read more here:
The Perfect 46 Super Bowl Commercial A - Video

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications: (1) the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen. The indications for ADCETRIS were authorized based on promising response rates demonstrated in single-arm trials. No data demonstrate increased survival with ADCETRIS.

We are focused on making ADCETRIS available globally to all eligible patients with relapsed HL and sALCL. The approval of ADCETRIS in Canada, as well as the recent approval in the European Union, are important milestones to accomplish this goal, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Now that Health Canada has approved ADCETRIS, we are committed to working closely with public and private insurers to secure reimbursement coverage for patients in Canada.

The approval of ADCETRIS in Canada marks a significant milestone for patients with relapsed HL or sALCL who have had few new treatment options in several decades, Joseph M. Connors, M.D., FRCPC, Clinical Director, Center for Lymphoid Cancer at BC Cancer Agency in Vancouver, Canada.

Health Canada grants NOC/c, a form of market approval, on the basis of promising evidence of clinical effectiveness, for products intended for the treatment of serious, life-threatening or severely debilitating illnesses that meet a serious unmet medical need or demonstrate a significant improvement in the benefit/risk profile over existing therapies. Conditions associated with market authorization under the NOC/c policy include a requirement that Seattle Genetics conduct clinical trials designed to confirm the anticipated clinical benefit of ADCETRIS in these patients. Two confirmatory phase III clinical trials evaluating ADCETRIS in the front-line treatment setting of HL and mature T-cell lymphoma (MTCL), including sALCL, are currently underway and enrolling patients.

ADCETRIS (brentuximab vedotin) was issued marketing authorization under the NOC/c policy based on results from a single-arm, phase II pivotal trial in HL patients with relapsed or refractory disease following an ASCT and a single-arm, phase II pivotal trial in relapsed or refractory sALCL patients. ADCETRIS is administered in hospitals through IV infusion over 30 minutes every three weeks and patients who achieve stable disease or better should receive a minimum of 8 cycles and up to a maximum of 16 cycles (approximately one year).

ADCETRIS is the first in a new class of antibody-drug conjugates (ADCs) to be approved in Canada. Using Seattle Genetics proprietary technology, the ADC consists of a monoclonal antibody directed to an antigen called CD30. The monoclonal antibody is connected to a cell-killing agent by a linker system that is designed to be stable in the bloodstream but to release the cell-killing agent into CD30-expressing cells, resulting in target cell death. The CD30 antigen is known to be expressed on the Reed-Sternberg cells of HL and on sALCL, an aggressive type of T-cell non-Hodgkin lymphoma.

Health Canadas approval of ADCETRIS is the first step in getting patients access to this important therapy, said Sue Robson, Executive Director of Lymphoma Foundation Canada. The Lymphoma Foundation is committed to working with Canada provincial governments to ensure that appropriate patients have access to this new therapy.

About Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also expresses CD30.

The rest is here:
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma ...

Recommendation and review posted by Bethany Smith

Precision StemCell - ALS Treatment with Gene Therapy and Stem Cells
http://www.precisionstemcell.com Dr. Jason R. Williams of Precision StemCell gives insight into a new concept of ALS treatment with gene therapy and stem cells.

By: PrecisionStemCell

See the article here:
Precision StemCell - ALS Treatment with Gene Therapy and Stem Cells - Video

Recommendation and review posted by Bethany Smith

Little Heroes
Synopsis: Canavan Disease is a rare genetic brain disorder that is unknown to most non-neurologists. It starts at birth with severe psychomotor delays and seizures, and leads to premature death. Until recently, no disease-modifying therapy has been available. This is the true story of Dr. Paola Leone and her team as they encounter the young patients who led them to undertake the first gene therapy for a neurodegenerative disease. Leone was approached by families with no expectation of a cure, but driven by a "forward-dawning hope" that their participation would redefine what is possible in modern therapy. Canavan Disease represents a striking example of people coming together to make medical history, and their cooperative efforts in search of a cure continue to this day. This film is about the "Little Heroes" who spearheaded the viral-based gene therapy which is now being applied in clinical trials for Parkinson #39;s, Alzheimer #39;s, and other disorders.

By: StudioImmagineArt

See the article here:
Little Heroes - Video

Recommendation and review posted by Bethany Smith

The Hope for Personalized Medicine in Myeloma
Dr. Mario Boccadoro, noted myeloma expert from Turin, Italy, shares his perspective on the improving prospects for patients with the disease. He also comments on efforts to tailor treatment for each patient in the quest for true "personalized medicine."

By: patientpower

Continued here:
The Hope for Personalized Medicine in Myeloma - Video

Recommendation and review posted by sam

Medicinal Rice P5 based Formuls for Spinal cord injury: Pankaj Oudhia #39;s Medicinal Plant Database
Septenary Ingredients of Important Traditional Herbal Formulations from Pankaj Oudhia #39;s Medicinal Plant Database Medicinal Plants of India with reference to Healing Flora of Andhra Pradesh, Assam, Karnataka, Kerala, Chhattisgarh, Gujarat, Jharkhand, Madhya Pradesh, Maharashtra, Meghalaya, Sikkim, Arunachal Pradesh, Orissa, Rajasthan, Tamilnadu, Punjab, Haryana, West Bengal, Uttarakhand and Uttar Pradesh. - This video is a part of Compilation of Pankaj Oudhia #39;s Research Works at Indira Gandhi Agricultural University, Raipur, India (1990-2001), - This video is a part of Pankaj Oudhia #39;s report on Endangered Species of India. - This video is a part of Pankaj Oudhia #39;s report on Forgotten Herbal Formulations of the World with special reference to Asia. - This video is a part of Pankaj Oudhia #39;s report on North American and European Medicinal Species in Traditional Healing of Asia. - This video is a part of Pankaj Oudhia #39;s Traditional Knowledge Database on Medicinal Rice based Herbal Formulations. - This video is a part of Pankaj Oudhia #39;s Dream Project to Establish International Medicinal Rice Research Institute (IMRRI) in India. For details please visit http://www.pankajoudhia.com

By: Pankaj Oudhia

See the original post here:
Medicinal Rice P5 based Formuls for Spinal cord injury: Pankaj Oudhia's Medicinal Plant Database - Video

Recommendation and review posted by sam

Jan. 31, 2013 New research has shown the presence of a disease affecting small blood vessels, known as microangiopathy, in the bone marrow of diabetic patients. While it is well known that microangiopathy is the cause of renal damage, blindness and heart attacks in patients with diabetes, this is the first time that a reduction of the smallest blood vessels has been shown in bone marrow, the tissue contained inside the bones and the main source of stem cells.

These precious cells not only replace old blood cells but also exert an important reparative function after acute injuries and heart attacks. The starvation of bone marrow as a consequence of microangiopathy can lead to a less efficient healing in diabetic patients. Also, stem cells from a patient's bone marrow are the most used in regenerative medicine trials to mend hearts damaged by heart attacks. Results from this study highlight an important deficit in stem cells and supporting microenvironment that can reduce stem cells' therapeutic potential in diabetic patients.

The research team, led by Professor Paolo Madeddu, Chair of Experimental Cardiovascular Medicine in the School of Clinical Sciences and Bristol Heart Institute at the University of Bristol, investigated the effect of diabetes on bone marrow stem cells and the nurturing of small blood vessels in humans.

The new study, published in the American Heart Association journal Circulation Research, was funded by the British Heart Foundation (BHF).

The researchers have shown a profound remodelling of the marrow, which shows shortage of stem cells and surrounding vessels mainly replaced by fat, especially in patients with a critical lack of blood supply to a tissue (ischaemia). This means that, as peripheral vascular complications progress, more damage occurs in the marrow. In a vicious cycle, depletion of bone marrow stem cells worsens the consequences of peripheral ischaemia.

Investigation of underpinning mechanisms revealed that exposure of bone marrow stem cells to the high glucose level typical of diabetes mellitus impacts on "microRNAs," which are tiny RNA molecules controlling gene expression and hence biological functions. In particular, microRNA-155, that normally controls the production of stem cells, becomes dramatically reduced in bone marrow cells exposed to high glucose. Diabetes-induced deficits are corrected by reintroducing microRNA-155 in human stem cells. The authors foresee that microRNAs could be used to regain proper stem cells number in diabetes and fix stem cells before reintroduction into a patient's body.

Professor Paolo Madeddu said: "Our study draws attention to the bone marrow as a primary target of diabetes-induced damage. The research suggests that the severity of systemic vascular disease has an impact on bone marrow causing a precocious senescence of stem cells. More severe bone marrow pathologies can cause, or contribute to, cardiovascular disease and lead to worse outcomes after a heart attack, through the shortage of vascular regenerative cells. Clinical evidence indicates that achieving a good control of glucose levels is fundamental to prevent vascular complications, but is less effective in correcting microangiopathy. We need to work hard to find new therapies for mending damaged microvessels."

Professor Costanza Emanueli, Chair of Vascular Pathology and Regeneration at the University of Bristol and co-author of the paper, added: "MicroRNAs represent an attractive means to repair the marrow damage and generate "better" stem cells for regenerative medicine applications. We are working at protocols using microRNA targeting for enhancing the therapeutic potential of stem cells before their transplantation to cure heart and limb ischaemia, which are often associated with diabetes mellitus. More work is, however, necessary before using this strategy in patients."

The findings advance the current understanding of pathological mechanisms leading to collapse of the vascular niche and reduced availability of regenerative cells. The data provides a key for interpretation of diabetes-associated defect in stem cell mobilisation following a heart attack. In addition, the research reveals a new molecular mechanism that could in the future become the target of specific treatments to alleviate vascular complications in patients with diabetes.

Professor Jeremy Pearson, Associate Medical Director at the BHF said: "Professor Madeddu and his team have shown for the first time that the bone marrow in patients with diabetes can't release stem cells which are important for the repair of blood vessel damage commonly found in people with the disease.

View post:
Diabetes distresses bone marrow stem cells by damaging their microenvironment

Recommendation and review posted by Bethany Smith

Admit it or not, as you age your skin starts showing signs that you would rather hide. Spots, wrinkles, and even crow's feet are just some of those signs that you would camouflage with makeup and skin creams to make them disappear-temporarily. But fear not, for beauty experts have discovered that stem cell treatment can also help in maintaining youthful skin.

According to Ma Fe Doria, a skin care expert, stem cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. As many may be aware, the most popular stem cell treatment is in Germany, where lots of celebrities and personalities (i.e. politicians) have flown to have stem cell injections for their ailments, using cells mostly harvested from the sheep. According to those who have undergone the procedure, the treatments have improved their body and the pains they've experienced have disappeared.

Today, many medical researchers continue to do experiments to determine if stem cell can help in curing various types of ailments from cancer to diabetes, which doctors have said may not be far behind. Aside from its healing benefits, stem cell is now being used by the beauty industry. Many cosmetic and beauty centers have started offering stem cell injections for the face, which is said to regenerate the skin where the cells are injected. While some continue to use sheep cells, plant and fat stem cells are now becoming the popular alternatives, with the fat stem cells being used to heal wounds, improve scars, and rejuvenate the skin.

But stem cell treatment is not cheap. Those who can afford it need to fly out of the country to avail of the treatment. Realizing the need in the market, Flawless Facial Center partnered with a local industry leader to produce Flawless' Stem Cell line, which uses the potent power of plant stem cells. Dubbed as the "superfood for the skin," Flawless' Stem Cell line is the epitome of skin nutrition.

"This new range of products allowed us to mark several milestones not just for Flawless but for the local beauty industry. Once again, we have taken something that, for the longest time, has remained exclusive to celebrities and other influential people, and made it affordable for the regular Juan and Juana," says Flawless ceo Ruby Sy.

For P2,500, the line includes a cleanser, day cream, and night serum. Flawless' Stem Cell line utilizes the plant stem cell technology to achieve the skin's youthful appearance by protecting it against oxidative stress and boosting the skin's repair and rejuvenation systems. "Times have really changed. No thanks to free radicals that are present in almost everything around us-from the food we eat to the air we breathe-people today age so much faster. This is especially true for people who like to spend late nights partying or spend too much time in front of the [TV/computer] monitor. Various studies have proven time and again the harmful effects such activities have on our skin," Sy said.

But with Flawless' latest baby, you can say goodbye to those ugly marks on your face. The Stem Cell line promises to solve all these, and more, by providing your skin with the right amount of nutrition and protection. Indeed, youthful glow is not only safe and available in a bottle, it's also now within reach of your pocket.

Go to http://www.flawless.com.ph for

store locations

Continue reading here:
Beauty Innovation: Young-looking skin with stem cell therapy

Recommendation and review posted by Bethany Smith

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA device). When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas. If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics.

ViaCyte's significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem cells. This portfolio includes 51 issued U.S. and foreign patents specifically directed to the Company's VC-01 product. In addition to the protection afforded by patents, the Company also relies on significant proprietary know-how to develop its product offerings.

Dr. Paul Laikind, ViaCyte's president and chief executive officer said, "Our comprehensive and growing intellectual property portfolio helps to establish us as a leading company in the cell therapy and regenerative medicine field. Although the Company's resources are currently fully committed to the rapid development of VC-01 as a potentially transformative treatment for patients with insulin-dependent diabetes, our platform technology has many other important applications."

In July and August of 2012, the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office (the "Board") also issued two decisions favoring ViaCyte on motions filed in the patent interference proceedings between ViaCyte and Geron Corporation (Menlo Park, California). The interferences involved ViaCyte's U.S. Patent No. 7,510,876 ("876 Patent"), which is directed to human definitive endoderm cell cultures in vitro. The Board upheld the claims of ViaCyte's '876 Patent in its entirety over Geron's applications. In September 2012, Geron appealed this decision in the United States District Court for the Northern District of California.

About ViaCyteViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

See the original post:
ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

Recommendation and review posted by Bethany Smith

PROVO A new discovery by BYU researchers may help doctors identify and better help patients with genetic potential for chemo and treatment resistance.

BYU and University of Iowa researchers discovered NEK2, a gene that seems to be a predictor of how cancer patients may react to therapy. When NEK2 is highly expressed, patients cancers often do not respond to chemotherapy, according to the study published in January in the journal Cancer Cell.

Just the expression of that gene could predict whether a patient would do well on therapy or not, said David Bearss, a BYU biology professor and co-author of the study. So that gene seemed to correlate with drug resistance.

NEK2 is found in normal dividing cells as well as cancer cells, but it becomes a problem as the levels increase.

Normal cells will have the NEK2 protein, but at much lower levels than the cancer cells, Bearss said. And really, thats how we distinguish patients that are predicted to do poorly versus ones that are predicted to do better on therapy is by the level of expression.

Michael Deininger, a physician and the chief of hematology at the University of Utah School of Medicine, said the research helps explain some of the main features of resistant cancer cells their instability and their ability to pump specific drugs out of the cells.

If it was, indeed, the case that NEK2 could be targeted and we would be able to shut down two major drug resistant mechanisms at the same time, that would be a very exciting development, Deininger said.

This breakthrough has positive ramifications for the cancer front: Doctors can give patients personalized treatment by examining NEK2 levels and, depending on how highly the gene is expressed, lead patients through a specialized, more aggressive process if needed.

Follow this link:
BYU professor co-authors breakthrough cancer research

Recommendation and review posted by Bethany Smith

Newswise Brian Kaspar, PhD, principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Childrens Hospital, along with a team of Spinal Muscular Atrophy (SMA) researchers and clinicians, received $650,000 in grants in 2012 from Sophias Cure Foundation for SMA research and Phase 1 clinical trial development which is set to launch in 2013. Working together with Nationwide Childrens, Sophias Cure Foundation has raised more than $2.3 million dollars for Dr. Kaspars program during the last three years alone.

Grant dollars from Sophias Cure Foundation are being used to support the pivotal studies required to submit an Investigational New Drug application to initiate human clinical trials in SMA patients which we hope to do in 2013, said Dr. Kaspar, also a faculty member at The Ohio State University College of Medicine. SMA research and therapeutic development stands to gain from this generous investment as we all look forward to translating our research to advance human clinical trials. Sophias Cure Foundation has been the lead funder of this program and their incredible investment in this lab has accelerated our program by many years. We are honored and extremely appreciative for this significant support.

Spinal Muscular Atrophy (SMA) is a group of inherited debilitating neurological diseases that cause progressive muscle degeneration and weakness throughout the body. There is no treatment for the progressive weakness which is caused by the disease. It is estimated that SMA occurs between one-in-6,000 and one-in-20,000 births. One-in-40 to one-in-80 normal men and women carry the gene for SMA, and if both a man and woman carry the gene, there is a 25 percent chance that any of their children will manifest SMA.

Sophias Cure Foundation is a non-profit public charity which was formed by the Gaynor family in New York City shortly after their daughter, Sophia, was diagnosed with Spinal Muscular Atrophy in 2009. The foundation was created to assist in funding for clinical research towards finding a cure for SMA and to offer support to families affected by this disease by providing advocacy, awareness, education and support. The foundation was formed three years ago by Vincent Gaynor, a One World Trade Center construction worker, and Catherine Gaynor, who left her job to care for Sophia when they learned she was sick. With their leadership and 100 percent volunteer involvement the foundation has raised more than $3 million for SMA research to date.

We run our foundation from the heart, because when you lead with your heart good things will always happen, said Vincent Gaynor, co-founder of Sophias Cure Foundation. People gravitate toward that. They believe in us and Sophia and know we will get the funds into the right hands to find a cure. Our partnership with Dr. Kaspar and Nationwide Childrens Hospital will yield great results for Spinal Muscular Atrophy research.

The rest is here:
Sophia's Cure Foundation Donates $650,000 in 2012 to Nationwide Children's Hospital for Dr. Brian Kaspar's Work in SMA ...

Recommendation and review posted by Bethany Smith

Public release date: 31-Jan-2013 [ | E-mail | Share ]

Contact: Marianne Slegers marianne.slegers@kcl.ac.uk 44-077-034-69550 King's College London

An international study led by King's College London has identified a new genetic variant associated with stroke. By exploring the genetic variants linked with blood clotting a process that can lead to a stroke scientists have discovered a gene which is associated with large vessel and cardioembolic stroke but has no connection to small vessel stroke.

Published in the journal Annals of Neurology, the study provides a potential new target for treatment and highlights genetic differences between different types of stroke, demonstrating the need for tailored treatments.

About 15 million people worldwide suffer a stroke each year. Of these, five million die and another five million are left permanently disabled, according to numbers from the World Health Organization (WHO). Risk factors for a stroke are high blood pressure, a heart rhythm disorder, high blood cholesterol, tobacco use, unhealthy diet, physical inactivity, diabetes and advancing age.

A stroke occurs when the blood supply to the brain is cut off, often due to a blood clot blocking an artery that carries blood to the brain, which then leads to brain cell damage. Coagulation (blood clotting) abnormalities, particularly easy clotting of the blood, are therefore common contributing factors in the development of stroke.

Dr Frances Williams, Senior Lecturer from the Department of Twin Research and Genetic Epidemiology at King's and lead author of the paper, said: 'Previous studies have demonstrated the influence of genetic factors on the components of coagulation. The goal of this study was to extend these observations to determine if they were further associated with different types of stroke.'

The research was carried out in three stages. The first consisted of a genome-wide association study (GWAS) in 2100 healthy volunteers which identified 23 independent genetic variants that were involved in coagulation. The second stage examined the 23 variants in 4200 stroke and non-stroke cases from centres across Europe (Wellcome Trust Case Control Consortium 2 and MORGAM collections) and found that a particular mutation on the ABO gene was significantly associated with stroke.

Stage three of the study used the MetaStroke cohort, a project of the International Stroke Genetics Consortium which comprises 8900 stroke cases recruited from centres in the Europe, USA and Australia, whose DNA has been collected and undergone GWA scan. It was confirmed that a variant in the ABO blood type gene was associated with stroke, a finding specific to large vessel and cardioembolic stroke.

Dr Williams said: 'The discovery of the association between this genetic variant and stroke identifies a new target for potential treatments, which could help to reduce the risk of stroke in the future. It is also significant that no association was found with small vessel disease, as this suggests that stroke subtypes involve different genetic mechanisms which emphasises the need for individualised treatment.'

More:
New stroke gene discovery could lead to tailored treatments

Recommendation and review posted by Bethany Smith